RudaCure was selected for the 2021 Bio-Medical Technology Development Project (Principal Investigator: Yuseung Ha) for its global expansion initiative. Through this project, the company will receive support until July of the same year for foundational research on establishing an overseas subsidiary and business collaboration for the U.S. clinical trials of the ophthalmic eye drop RCI001.
In the project evaluation, the company was recognized for its excellent R&D and commercialization progress and analysis, as well as its clear global startup goals. The company was selected by recognizing the marketability and future potential of RCI001 in a world where no fundamental treatment drug for dry eye disease currently exists.
This project will select 5 companies through a first-round evaluation and provide annual support of KRW 300 million per year for 3 years for global expansion activities.